Astellas Pharma Inc. has entered a phase of strong collaboration and expansion, with several significant announcements. It has collaborated with
YASKAWA for aninnovative cell therapy ecosystem, the
UMass Chan Medical School,
Poseida Therapeutics, and
Kelonia Therapeutics for novel oncology therapies. In a master venture agreement with
Takeda and
Sumitomo Mitsui Banking, Astellas aims to accelerate early drug discovery programs. Operations have further scaled up with the acquisition of
Propella Therapeutics and development of a
$90 Million West Coast Innovation Center. FDA approval has been gained for a combination therapy for bladder cancer, while it seeks approval for zolbetuximab and Eye Drug Izervay in the US and Europe. Meanwhile, positive CHMP opinions have been received for treating advanced bladder cancer, vasomotor symptoms associated with menopause, advanced gastric and gastroesophageal junction cancer. Critical resources are being routed to patients via the Patient Advocacy Organization Action Week™. Despite some earnings missing estimates and the FDA declining approval for a gastric cancer drug, Astellas' focus continues to escalate in the realms of therapy, patient support, and sustainable practices.
Astellas Pharma Inc. News Analytics from Wed, 31 May 2017 16:44:13 GMT to Sun, 04 Aug 2024 00:16:13 GMT -
Rating 5
- Innovation 8
- Information 8
- Rumor 4
